Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.73 |
| ▸ | NPC1 | O15118 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | DHODH | Q02127 | 2/20 | 0.68 |
| ▸ | TOP1 | P11387 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.62 |
| ▸ | RELA | Q04206 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 2/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.60 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16276170 | 0.85 | NPC1 (0.78) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL3053529 | 0.84 | NPC1 (1.00) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7349336 | 0.84 | SCD (0.73) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30582282 | 0.84 | NPC1 (0.74) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4920234 | 0.84 | SCD (0.73) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1354240 | 0.84 | NPC1 (0.74) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4909148 | 0.84 | NPC1 (0.74) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL8552971 | 0.84 | SCD (1.00) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12963275 | 0.83 | MAPT (0.72) | MEN1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL2482821 | 0.82 | SCD (0.83) | SCDNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | SCD 3790/4885NPC1 1713/4885RAB9A 3792/4885 |
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | SCD 1571/4885NPC1 1196/4885RAB9A 616/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | SCD 3956/4885NPC1 3462/4885RAB9A 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.